

## Medtronic Diabetes secures Health Canada licence for the Medtronic Guardian™ 4 Sensor with the MiniMed™ 780G system

Today, Medtronic Canada announced that it has received a licence from Health Canada for the Guardian™ 4 sensor to be used in conjunction with the MiniMed™ 780G insulin pump system† for the management of type 1 diabetes.

The MiniMed 780G system is designed to offer more control with less effort for people living with type 1 diabetes. Currently available and integrated with the Guardian Sensor (3), the MiniMed 780G system is the only advanced hybrid closed loop system in Canada that can automatically adjust and correct sugars every 5 minutes\* thanks to the company's innovative algorithm known as SmartGuard™ technology. The system provides meal detection technology, a component of SmartGuard™, and auto correction boluses of insulin to help account for when users occasionally forget to bolus or underestimate the number of carbs in their meal. The addition of the new Guardian™ 4 sensor is another step towards reducing the burden of managing diabetes for insulin pump users, by removing the need for fingersticks with SmartGuard technology\*\*.

“With the recent launch of the world's first and only insulin pump system with meal detection technology, we are hearing from our MiniMed 780G system users that it's helping increase their time in range<sup>1</sup> and the improved usability of our system is already making a significant impact on their day-to-day lives,” said Laura Cameron, senior director of Endocrinology at Medtronic Canada. “We're thrilled to expand our innovative solutions that help simplify diabetes management with the goal of making lives easier for those we have the privilege to support.”

The company expects to launch the new sensor commercially by the end of 2023. Learn more about the benefits of the MiniMed 780G system, today integrated with the Guardian Sensor (3), and how to access it at [medtronicdiabetes.ca/MiniMed780G](https://medtronicdiabetes.ca/MiniMed780G).

Follow us on [Twitter](#), [LinkedIn](#), [Instagram](#) and [Facebook](#)

For more information, contact :

Roxane Bélanger  
Public Relations  
+1- 905-460-3800

Ryan Weispfenning  
Investor Relations  
+1-763-505-4626

The MiniMed™ 780G insulin pump is indicated for use by patients age 7-80 years with type 1 diabetes, whose total daily dose of insulin is 8 units per day or more.

†Guardian™ 4 sensor licensed for use with MiniMed™ 780G Prime A2

\*Refers to SmartGuard™ feature. Some user interaction is required. Individual results may vary.

\*\*A blood glucose (BG) reading needed to enter SmartGuard™ feature. If symptoms don't match alerts & readings, use a BG meter. Refer to user guide. Pivotal trial participants spend avg of 95% in SmartGuard.

(1) Carlson AL, Sherr JL, Shulman DI, et al. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. *Diabetes Technology & Therapeutics*. 2021;24(3):178-189.

---

<https://canadanews.medtronic.com/Medtronic-Diabetes-secures-Health-Canada-licence-for-the-Medtronic-Guardian-TM-4-Sensor-with-the-MiniMed-TM-780G-system?sf177460171=1>